186 related articles for article (PubMed ID: 20054688)
21. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein.
Shimizu K; Thomas EK; Giedlin M; Mulé JJ
Cancer Res; 2001 Mar; 61(6):2618-24. PubMed ID: 11289139
[TBL] [Abstract][Full Text] [Related]
22. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
[TBL] [Abstract][Full Text] [Related]
23. Imiquimod enhances the potency of an exogenous BM-DC based vaccine against mouse melanoma.
Ren S; Wang Q; Zhang Y; Song Y; Dong X; Zhang W; Qin X; Liu M; Yu T
Int Immunopharmacol; 2018 Nov; 64():69-77. PubMed ID: 30149266
[TBL] [Abstract][Full Text] [Related]
24. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
25. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
26. Epstein Barr virus Latent Membrane Protein-1 enhances dendritic cell therapy lymph node migration, activation, and IL-12 secretion.
Termini JM; Gupta S; Raffa FN; Guirado E; Fischl MA; Niu L; Kanagavelu S; Stone GW
PLoS One; 2017; 12(9):e0184915. PubMed ID: 28910387
[TBL] [Abstract][Full Text] [Related]
27. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
Tanaka Y; Koido S; Ohana M; Liu C; Gong J
J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
[TBL] [Abstract][Full Text] [Related]
28. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow.
Yang S; Darrow TL; Vervaert CE; Seigler HF
Cell Immunol; 1997 Jul; 179(1):84-95. PubMed ID: 9259775
[TBL] [Abstract][Full Text] [Related]
30. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.
Ito F; Li Q; Shreiner AB; Okuyama R; Jure-Kunkel MN; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2004 Nov; 64(22):8411-9. PubMed ID: 15548712
[TBL] [Abstract][Full Text] [Related]
31. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
Aravindaram K; Wang PH; Yin SY; Yang NS
Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
[TBL] [Abstract][Full Text] [Related]
32. Conditioning of the injection site with CpG enhances the migration of adoptively transferred dendritic cells and endogenous CD8+ T-cell responses.
Tripp CH; Ebner S; Ratzinger G; Romani N; Stoitzner P
J Immunother; 2010; 33(2):115-25. PubMed ID: 20145551
[TBL] [Abstract][Full Text] [Related]
33. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
34. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule.
Johnson TS; Mahnke K; Storn V; Schönfeld K; Ring S; Nettelbeck DM; Haisma HJ; Le Gall F; Kontermann RE; Enk AH
Clin Cancer Res; 2008 Dec; 14(24):8169-77. PubMed ID: 19088032
[TBL] [Abstract][Full Text] [Related]
36. Low molecular weight hyaluronan preconditioning of tumor-pulsed dendritic cells increases their migratory ability and induces immunity against murine colorectal carcinoma.
Alaniz L; Rizzo M; Garcia MG; Piccioni F; Aquino JB; Malvicini M; Atorrasagasti C; Bayo J; Echeverria I; Sarobe P; Mazzolini G
Cancer Immunol Immunother; 2011 Oct; 60(10):1383-95. PubMed ID: 21638126
[TBL] [Abstract][Full Text] [Related]
37. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
38. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells.
Chen Z; Moyana T; Saxena A; Warrington R; Jia Z; Xiang J
Int J Cancer; 2001 Aug; 93(4):539-48. PubMed ID: 11477558
[TBL] [Abstract][Full Text] [Related]
39. Imiquimod combined with dendritic cell vaccine decreases Treg proportion and enhances anti-tumor responses in mice bearing melanoma.
Ren S; Wang Q; Zhang Y; Lu C; Li P; Li Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Feb; 33(2):145-50. PubMed ID: 29762000
[TBL] [Abstract][Full Text] [Related]
40. Antitumor reactivity of lymph node cells primed in vivo with dendritic cell-based vaccines.
Tanigawa K; Takeshita N; Eickhoff GA; Shimizu K; Chang AE
J Immunother; 2001; 24(6):493-501. PubMed ID: 11759072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
